Overall BIIB gets a fundamental rating of 6 out of 10. We evaluated BIIB against 525 industry peers in the Biotechnology industry. BIIB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BIIB is valued quite cheap, but it does not seem to be growing. With these ratings, BIIB could be worth investigating further for value investing!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.28 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.44 | ||
| Fwd PE | 11.32 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.34 | ||
| EV/EBITDA | 7.65 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 6 / 10 to BIIB.
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.
BIOGEN INC (BIIB) has a profitability rating of 7 / 10.
The financial health rating of BIOGEN INC (BIIB) is 7 / 10.